115 results on '"Solimani, F."'
Search Results
2. Pharmakologie der Januskinaseinhibitoren
3. 219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid
4. 048 Dysfunctional transitional B cells in patients with pemphigus
5. Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS‐CoV‐2 in patients with pemphigus and bullous pemphigoid
6. 034 Impaired frequency and function of transitional B cells in patients with pemphigus vulgaris
7. Paradoxical lichen planus induced during anti‐IL‐17A treatment is immunologically different from spontaneously occurring lichen planus
8. 029 Deciphering the functionality of T regulatory subsets in pemphigus
9. 289 The effect of immune checkpoint Inhibitors on the CD4+ T-cell population by patients with advanced melanoma and the role of these cells in immune related adverse events
10. Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2
11. 029 Transcriptome analysis suggests a role of IL-17-related genes in pemphigus
12. Diffuse vegetating bromoderma
13. 080 Modulation of the T helper and T follicular helper cell distribution in pemphigus patients by B cell-depleting therapy
14. 079 Detection and monitoring of autoreactive T cell responses against desmoglein 1 and 3 in patients with pemphigus
15. Successful treatment of cheilitis granulomatosa with lenalidomide
16. Modulation of the T helper and T follicular helper cell distribution in pemphigus patients by B cell-depleting therapy
17. Diagnosis of anti‐laminin γ‐1 pemphigoid by immunoblot analysis
18. Basal cell carcinoma of the scrotum: an important but easily overlooked entity
19. Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis
20. 038 Therapeutic efficacy of IL-17 blockade identifies lichen planus as a Th17-driven skin disorder
21. 484 Lichen planus pemphigoides is a chimera of lichen planus and bullous pemphigoid
22. Diagnosis of anti‐laminin γ‐1 pemphigoid by immunoblot analysis.
23. Diffuse vegetating bromoderma.
24. Type 17 T follicular helper cells promote desmoglein 1/3-specific autoantibody production in pemphigus
25. Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review
26. [Monoclonal antibodies for inflammatory, autoimmune and oncological skin diseases].
27. [Janus kinase inhibitors for skin disorders].
28. Pathogenic relevance of antibodies against desmoglein 3 in patients with oral lichen planus.
29. Fatal course of cutaneous mucormycosis in an immunosuppressed patient.
30. A patient with concomitant epidermolysis bullosa acquisita, acquired hemophilia and disseminated warts.
31. TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus.
32. Alterations of circulating free fatty acids in patients with pemphigus vulgaris.
33. Non-biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases.
34. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris.
35. Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease.
36. Größer werdende gelbliche indurierte Plaques am Hals und in den Achselhöhlen.
37. Progressive enlarging yellowish indurated plaques on the neck and armpits.
38. Pemphigus- und Pemphigoid-Erkrankungen: Klinik, Diagnostik und Therapie: Pemphigus and pemphigoids: Clinical presentation, diagnosis and therapy.
39. Pemphigus and pemphigoids: Clinical presentation, diagnosis and therapy.
40. Zertifizierung: "Führen in der Dermatologie (DDA)".
41. Upadacitinib for treatment-resistant Lichen amyloidosis.
42. Interleukin-21 in autoimmune and inflammatory skin diseases.
43. Dermatomyositis: a comprehensive review of clinical manifestations, serological features, and therapeutic approaches.
44. Enzymatic Debridement in Geriatric Burn Patients-A Reliable Option for Selective Eschar Removal.
45. The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus.
46. The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.
47. Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS.
48. Therapeutic strategies for oral lichen planus: State of the art and new insights.
49. Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris.
50. Subunit-Specific Reactivity of Autoantibodies Against Laminin-332 Reveals Direct Inflammatory Mechanisms on Keratinocytes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.